Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Somatostatinoma 2Carcinoma, Islet Cell 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymus Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Pheochromocytoma 1Pharyngeal Neoplasms 1Penile Neoplasms 1Parotid Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1

Interventions

Capecitabine 4Temozolomide 3Octreotide 3Leucovorin 3Everolimus 3vatalanib 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Streptozocin 1Sorafenib 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Gefitinib 1Floxuridine 1Fentanyl 1Doxorubicin 1Cisplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrinoma × Biological Therapy × Endocrine × Clear all
NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡